| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 Oxford University Press
COMMENTARY |
Lessons from Controversy: Ovarian Cancer Screening and Serum Proteomics
Affiliations of author: Departments of Medicine and Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC
Correspondence to: David F. Ransohoff, MD, Departments of Medicine and Epidemiology, University of North Carolina at Chapel Hill, CB# 7080, Bioinformatics Bldg. 4103, Chapel Hill, NC 27599-7080 (e-mail: ransohof{at}med.unc.edu).
In 2002 a study reported that a blood test, based on pattern-recognition proteomics mass spectroscopy analysis of serum, was nearly 100% sensitive and specific to detect ovarian cancer. Plans to introduce a commercial screening test by early 2004 were delayed amid concerns about whether the approach was reproducible and reliable. In this issue of JNCI, two commentaries discuss whether the initial results are reproducible and whether bias may account for results. This essay describes how threats to validity from chance and bias may cause erroneous results and inflated expectations in the kind of observational research being conducted in several "-omics" fields to assess molecular markers for diagnosis and prognosis of cancer. To address such threats and to realize the potential of new -omics technology will require application of appropriate rules of evidence in the design, conduct, and interpretation of clinical research about molecular markers.
CiteULike 
Connotea 
Del.icio.us What's this?
Correspondence about this Article
- Re: Lessons from Controversy: Ovarian Cancer Screening and Serum Proteomics
- Ronghui Xu and Anthony Gamst
J Natl Cancer Inst 2005 97: 1226.[Extract] [Full Text] [PDF]
Related Article in JNCI
- Importance of Communication Between Producers and Consumers of Publicly Available Experimental Data
- Lance A. Liotta, Mark Lowenthal, Arpita Mehta, Thomas P. Conrads, Timothy D. Veenstra, David A. Fishman, and Emanuel F. Petricoin, III
J Natl Cancer Inst 2005 97: 310-314.[Abstract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  J. M.G. Taylor, D. P. Ankerst, and R. R. Andridge Validation of Biomarker-Based Risk Prediction Models Clin. Cancer Res., October 1, 2008; 14(19): 5977 - 5983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zhang, C. Yao, Z. Guo, J. Zou, L. Zhang, H. Xiao, D. Wang, D. Yang, X. Gong, J. Zhu, et al. Apparently low reproducibility of true differential expression discoveries in microarray studies Bioinformatics, September 15, 2008; 24(18): 2057 - 2063. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Tworoger, D. Spentzos, F. T. Grall, T. A. Liebermann, and S. E. Hankinson Reproducibility of Proteomic Profiles Over 3 Years in Postmenopausal Women Not Taking Postmenopausal Hormones Cancer Epidemiol. Biomarkers Prev., June 1, 2008; 17(6): 1480 - 1485. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Carvalho, C. Jeronimo, M. M. Kim, R. Henrique, Z. Zhang, M. O. Hoque, S. Chang, M. Brait, C. S. Nayak, W.-W. Jiang, et al. Evaluation of Promoter Hypermethylation Detection in Body Fluids as a Screening/Diagnosis Tool for Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., January 1, 2008; 14(1): 97 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. McLerran, W. E. Grizzle, Z. Feng, I. M. Thompson, W. L. Bigbee, L. H. Cazares, D. W. Chan, J. Dahlgren, J. Diaz, J. Kagan, et al. SELDI-TOF MS Whole Serum Proteomic Profiling with IMAC Surface Does Not Reliably Detect Prostate Cancer Clin. Chem., January 1, 2008; 54(1): 53 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hundt, U. Haug, and H. Brenner Blood Markers for Early Detection of Colorectal Cancer: A Systematic Review Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 1935 - 1953. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Lumbreras, M. Porta, and I. Hernandez-Aguado Assessing the social meaning, value and implications of research in genomics J. Epidemiol. Community Health, September 1, 2007; 61(9): 755 - 756. [Full Text] [PDF]
|
|
|
|
|
|
F. K. Parekh and T. L. Richie Characterization of Immune Reactivity Profiles Using Microarray Technology May Expedite Identification of Candidate Antigens for Next Generation Malaria Vaccines Clin. Chem., July 1, 2007; 53(7): 1183 - 1185. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Y. Karlan and M. McIntosh The Quest for Ovarian Cancer's Holy Grail: Can CA-125 Still Be the Chalice of Early Detection? J. Clin. Oncol., April 10, 2007; 25(11): 1303 - 1304. [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Kyzas, D. Denaxa-Kyza, and J. P. A. Ioannidis Quality of Reporting of Cancer Prognostic Marker Studies: Association With Reported Prognostic Effect J Natl Cancer Inst, February 7, 2007; 99(3): 236 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Mason, T. M. Therneau, J. E. Eckel-Passow, K. L. Johnson, A. L. Oberg, J. E. Olson, K. S. Nair, D. C. Muddiman, and H. R. Bergen III A Method for Automatically Interpreting Mass Spectra of 18O-Labeled Isotopic Clusters Mol. Cell. Proteomics, February 1, 2007; 6(2): 305 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Lance The Cancer Genome and Diagnostic Blood Tests. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2017 - 2018. [Full Text] [PDF]
|
|
|
|
|
|
D. Nedelkov, U. A. Kiernan, E. E. Niederkofler, K. A. Tubbs, and R. W. Nelson Population Proteomics: The Concept, Attributes, and Potential for Cancer Biomarker Research Mol. Cell. Proteomics, October 1, 2006; 5(10): 1811 - 1818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Drake, E. E. Schwegler, G. Malik, J. Diaz, T. Block, A. Mehta, and O. J. Semmes Lectin Capture Strategies Combined with Mass Spectrometry for the Discovery of Serum Glycoprotein Biomarkers Mol. Cell. Proteomics, October 1, 2006; 5(10): 1957 - 1967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Moore, E. T. Fung, M. McGuire, C. C. Rabkin, A. Molinaro, Z. Wang, F. Zhang, J. Wang, C. Yip, X.-Y. Meng, et al. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol. Biomarkers Prev., September 1, 2006; 15(9): 1641 - 1646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Barker, P. D. Wagner, S. E. Stein, D. M. Bunk, S. Srivastava, and G. S. Omenn Standards for Plasma and Serum Proteomics in Early Cancer Detection: A Needs Assessment Report from the National Institute of Standards and Technology-National Cancer Institute Standards, Methods, Assays, Reagents and Technologies Workshop, August 18-19, 2005 Clin. Chem., September 1, 2006; 52(9): 1669 - 1674. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. P. Diamandis Serum Proteomic Profiling by Matrix-Assisted Laser Desorption-Ionization Time-of-Flight Mass Spectrometry for Cancer Diagnosis: Next Steps Cancer Res., June 1, 2006; 66(11): 5540 - 5541. [Full Text] [PDF]
|
|
|
|
 |
|
 J. P A Ioannidis Commentary: Grading the credibility of molecular evidence for complex diseases Int. J. Epidemiol., June 1, 2006; 35(3): 572 - 578. [Full Text] [PDF]
|
|
|
|
|
|
R. C Millikan Commentary: The Human Genome: philosopher's stone or magic wand? Int. J. Epidemiol., June 1, 2006; 35(3): 578 - 581. [Full Text] [PDF]
|
|
|
|
 |
|
 M. W. Duncan and S. W. Hunsucker Proteomics as a Tool for Clinically Relevant Biomarker Discovery and Validation Experimental Biology and Medicine, December 1, 2005; 230(11): 808 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Findeisen, D. Sismanidis, M. Riedl, V. Costina, and M. Neumaier Preanalytical Impact of Sample Handling on Proteome Profiling Experiments with Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Clin. Chem., December 1, 2005; 51(12): 2409 - 2411. [Full Text] [PDF]
|
|
|
|
|
|
T. W. Randolph, B. L. Mitchell, D. F. McLerran, P. D. Lampe, and Z. Feng Quantifying Peptide Signal in MALDI-TOF Mass Spectrometry Data Mol. Cell. Proteomics, December 1, 2005; 4(12): 1990 - 1999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Honda, Y. Hayashida, T. Umaki, T. Okusaka, T. Kosuge, S. Kikuchi, M. Endo, A. Tsuchida, T. Aoki, T. Itoi, et al. Possible Detection of Pancreatic Cancer by Plasma Protein Profiling Cancer Res., November 15, 2005; 65(22): 10613 - 10622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Zhang and D. W. Chan Cancer Proteomics: In Pursuit of "True" Biomarker Discovery Cancer Epidemiol. Biomarkers Prev., October 1, 2005; 14(10): 2283 - 2286. [Full Text] [PDF]
|
|
|
|
|
|
N. L. Anderson The Roles of Multiple Proteomic Platforms in a Pipeline for New Diagnostics Mol. Cell. Proteomics, October 1, 2005; 4(10): 1441 - 1444. [Full Text] [PDF]
|
|
|
|
|
|
O. J. Semmes The "omics" Haystack: Defining Sources of Sample Bias in Expression Profiling Clin. Chem., September 1, 2005; 51(9): 1571 - 1572. [Full Text] [PDF]
|
|
|
|
|
|
R. Xu and A. Gamst Re: Lessons from Controversy: Ovarian Cancer Screening and Serum Proteomics J Natl Cancer Inst, August 17, 2005; 97(16): 1226 - 1226. [Full Text] [PDF]
|
|
|
|
|
|
S. R. Master Diagnostic Proteomics: Back to Basics? Clin. Chem., August 1, 2005; 51(8): 1333 - 1334. [Full Text] [PDF]
|
|
|
|
|
|
A. Karsan, B. J. Eigl, S. Flibotte, K. Gelmon, P. Switzer, P. Hassell, D. Harrison, J. Law, M. Hayes, M. Stillwell, et al. Analytical and Preanalytical Biases in Serum Proteomic Pattern Analysis for Breast Cancer Diagnosis Clin. Chem., August 1, 2005; 51(8): 1525 - 1528. [Full Text] [PDF]
|
|
|
|
|
|
M. Goggins Molecular Markers of Early Pancreatic Cancer J. Clin. Oncol., July 10, 2005; 23(20): 4524 - 4531. [Abstract] [Full Text] [PDF]
|
|